MaxCyte reports Q3 results

* MaxCyte press release [https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-reports-third-quarter-2025-financial-results-and] (MXCT [https://seekingalpha.com/symbol/MXCT]): Q3 net loss was $12.4 million compared to net loss of $11.6 million for the same period in 2024.
* Revenue of $6.8M (-17.1% Y/Y).
* MaxCyte reiterates 2025 revenue guidance for core business revenue and SPL Program-related revenue: Core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx.
* SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.

MORE ON MAXCYTE

* MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4842835-maxcyte-inc-mxct-q3-2025-earnings-call-transcript]
* MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance [https://seekingalpha.com/news/4521043-maxcyte-outlines-17m-19m-annualized-savings-through-restructuring-while-reiterating-spl]
* MaxCyte announces 34% workforce reduction to cut costs [https://seekingalpha.com/news/4497465-maxcyte-announces-34-workforce-reduction-to-cut-costs]
* Seeking Alpha’s Quant Rating on MaxCyte [https://seekingalpha.com/symbol/MXCT/ratings/quant-ratings]
* Historical earnings data for MaxCyte [https://seekingalpha.com/symbol/MXCT/earnings]